NCT02337426View on ClinicalTrials.gov

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 13, 2015

Primary Completion Date

November 8, 2016

Study Completion Date

November 9, 2017

Conditions
Adult Brain GlioblastomaAdult Giant Cell GlioblastomaAdult Gliosarcoma
Interventions
DRUG

Dimethyl Fumarate

Given PO

DRUG

Temozolomide

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT02337426 - Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter